Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous menstrual blood-derived mesenchymal stromal cells
- Development stage
- Phase 3
- Lead developer
- Avicenna Research Institute
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraovarian Injection
01
Overview
Autologous menstrual blood-derived mesenchymal stromal cells (MenSCs) is an experimental cell therapy developed by the Avicenna Research Institute for the treatment of poor ovarian response (POR) in women undergoing fertility treatments. The therapy involves the isolation of mesenchymal stromal cells from the patient's own menstrual blood, which are then cultured, expanded in vitro, and administered via bilateral intraovarian injection under ultrasound guidance. The mechanism of action is believed to involve the regeneration of ovarian tissue and restoration of function through the cells' differentiation potential and the secretion of paracrine factors. Clinical studies, including a Phase III trial in Iran, have demonstrated improvements in ovarian reserve markers such as anti-Müllerian hormone (AMH) levels and antral follicle count (AFC), as well as increased pregnancy rates in patients who previously failed to respond to conventional stimulation protocols.
- Other names
- Autologous Menstrual Blood Stem CellsMenstrual Blood-Derived Mesenchymal Stem Cells
Beyond the preview
Go deeper on autologous menstrual blood-derived mesenchymal stromal cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous menstrual blood-derived mesenchymal stromal cells.